High levels of adherence do not prevent accumulation of HIV drug resistance mutations.
about
Randomized, controlled trial of therapy interruption in chronic HIV-1 infectionCerebrospinal fluid HIV infection and pleocytosis: relation to systemic infection and antiretroviral treatmentAdherence to HAART: a systematic review of developed and developing nation patient-reported barriers and facilitatorsPharmacy refill adherence compared with CD4 count changes for monitoring HIV-infected adults on antiretroviral therapyHidden drug resistant HIV to emerge in the era of universal treatment access in Southeast AsiaAdherence as a predictor of the development of class-specific resistance mutations: the Swiss HIV Cohort StudyFactors associated with adherence to antiretroviral therapy among adolescents living with HIV/AIDS in low- and middle-income countries: a systematic review.HIV epidemiology and the effects of antiviral therapy on long-term consequences.Designed, synthetically accessible bryostatin analogues potently induce activation of latent HIV reservoirs in vitroDevelopment of a nursing intervention to facilitate optimal antiretroviral-treatment taking among people living with HIV.The risk of virologic failure decreases with duration of HIV suppression, at greater than 50% adherence to antiretroviral therapy.Lost but not forgotten--the economics of improving patient retention in AIDS treatment programs.A randomized controlled trial of a peer support intervention targeting antiretroviral medication adherence and depressive symptomatology in HIV-positive men and women.Density of healthcare providers and patient outcomes: evidence from a nationally representative multi-site HIV treatment program in UgandaSelf-report measures of antiretroviral therapy adherence: A review with recommendations for HIV research and clinical management.Evidence that low-level viremias during effective highly active antiretroviral therapy result from two processes: expression of archival virus and replication of virus.Follow-Up Visit Patterns in an Antiretroviral Therapy (ART) programme in Zomba, Malawi.Sero-positive African Americans' beliefs about alcohol and their impact on anti-retroviral adherence.How qualitative methods contribute to understanding combination antiretroviral therapy adherence.Evaluating interventions to improve antiretroviral adherence: how much of an effect is required for favorable value?Disparities in HIV treatment and physician attitudes about delaying protease inhibitors for nonadherent patientsResponse to zidovudine/didanosine-containing combination antiretroviral therapy among HIV-1 subtype C-infected adults in Botswana: two-year outcomes from a randomized clinical trial.Using concept mapping to explore why patients become lost to follow up from an antiretroviral therapy program in the Zomba District of Malawi.Early virologic failure and the development of antiretroviral drug resistance mutations in HIV-infected Ugandan children.Viral suppression and antiretroviral medication adherence among alcohol using HIV-positive adultsPredicting the epidemiological impact of antiretroviral allocation strategies in KwaZulu-Natal: the effect of the urban-rural divideEffect of home-based interventions on virologic outcomes in adults receiving antiretroviral therapy in Africa: a meta-analysisSocial factors affecting ART adherence in rural settings in Zambia.Implementation and operational research: evaluating outcomes of patients lost to follow-up in a large comprehensive care treatment program in western Kenya.An update on the use of Atripla in the treatment of HIV in the United States.Antiretroviral therapy in Africa.Baseline resistance to nucleoside reverse transcriptase inhibitors fails to predict virologic response to combination therapy in children (PACTG 338).Readiness in HIV Treatment Adherence: A Matter of Confidence. An Exploratory Study.Patient-related factors predicting HIV medication adherence among men and women with alcohol problemsUnannounced telephone-based pill counts: a valid and feasible method for monitoring adherence.Community Perceptions of Community Health Workers (CHWs) and Their Roles in Management for HIV, Tuberculosis and Hypertension in Western KenyaDurability of adherence to antiretroviral therapy on initial and subsequent regimens.Identifying common barriers and facilitators to linkage and retention in chronic disease care in western KenyaAn empirical test of the information, motivation and behavioral skills model of antiretroviral therapy adherence.Adherence, virological and immunological outcomes for HIV-infected veterans starting combination antiretroviral therapies.
P2860
Q24809608-E70F38C3-A6B7-471D-BB83-62EEA1F7101FQ24814874-8EBF80AA-3701-4A3B-8032-3D41071F8483Q28469073-1C61C526-6701-44BB-95BA-9277C57FCA74Q28472810-E990EC82-A15D-46C9-BF00-CE497B876810Q28474290-0004121D-916F-46CA-A3DF-452498E71FAAQ28534423-E0938588-B9E7-49D2-85D0-878673410BA1Q30371970-D9840C13-27EA-4AB0-BDBB-ADC225A1D7A0Q30372536-F93B345B-02A8-4863-AE58-8FDB2E989EE1Q30558754-62B9984D-E9F4-4967-AA3A-07A424E0F7E1Q33477968-021FFB03-99BB-4E88-920C-E239F373618CQ33507274-816BFB74-ACE8-4628-AAC1-0625D90E1DD9Q33512904-04B3047B-0FAC-4FD5-9453-7526BBEFB820Q33707675-DD0BA6B5-4680-4720-8504-8F9961351B43Q33802583-6096E159-DC54-4B1D-9B4B-6516A3FBA8A2Q33851716-E5CDB3A6-0F8B-49E2-92AF-23C3F98A952EQ33908838-98899FCD-0460-4EE1-8710-68FBAE3E77C0Q33916232-0D023467-52CF-44DF-9CB7-C5498BB4C9BAQ34437428-FB110A81-CE60-4884-8C1A-AAAF287A9C97Q34438311-1F129480-0540-4389-890F-0A39BC7A56E6Q34546423-518E6772-064F-4AD2-BC5F-36A7C869D082Q34732022-17F10755-61F9-41D9-991A-854727969E72Q34732899-FC332C1B-EB49-48FF-AAC7-3B1CF5EF0393Q34768487-E746D27E-8289-4EF9-9A76-6D9497077002Q34803017-87938324-8284-4271-BF02-525832DF7DC1Q34817650-46FC2AEE-F2C1-41D0-9958-CD0F95E4F359Q35080552-7E386399-C887-4BF5-BCFA-B9217A750BEEQ35114171-1850E949-3849-44B2-9ED4-7DAA81B153D1Q35130381-DD12311E-0497-4D27-94C0-EF53DE8C69B6Q35142277-62E299F6-C266-42DB-A28C-41DBBAFAE3E5Q35557269-5C48791F-7C4D-4791-A3AF-BBD6925E0916Q35643060-2B9456FD-2F36-4500-BA22-A41CBB6675D8Q35647376-2090C2B8-4E55-4E34-B57A-3BF84F976A42Q35671398-31D0F2F7-CAE8-4C3E-9B12-62365810A696Q35758118-AC708508-14EB-4E38-9283-4830FA213541Q35831773-8B673274-5405-43CD-8908-C6BC8B2C3E43Q35931438-9BC7CCFC-991E-46F2-94A9-BD9DE476D2FFQ35990464-68ABC717-1881-4DFB-965C-D753ED01436FQ36098213-80412796-FBC3-465D-8735-958767AF9205Q36203449-2547B865-7B2A-4F9B-B293-C71398CE2D4EQ36285950-0AFF8A33-42BC-461C-8DA0-099A31826C46
P2860
High levels of adherence do not prevent accumulation of HIV drug resistance mutations.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
2003年论文
@zh
2003年论文
@zh-cn
name
High levels of adherence do not prevent accumulation of HIV drug resistance mutations.
@en
High levels of adherence do not prevent accumulation of HIV drug resistance mutations.
@nl
type
label
High levels of adherence do not prevent accumulation of HIV drug resistance mutations.
@en
High levels of adherence do not prevent accumulation of HIV drug resistance mutations.
@nl
prefLabel
High levels of adherence do not prevent accumulation of HIV drug resistance mutations.
@en
High levels of adherence do not prevent accumulation of HIV drug resistance mutations.
@nl
P2093
P50
P1433
P1476
High levels of adherence do not prevent accumulation of HIV drug resistance mutations.
@en
P2093
Andrew Moss
Andrew Zolopa
David Guzman
Kathleen Nugent Conroy
Richard Clark
Sharon Perry
P304
P356
10.1097/00002030-200309050-00011
P407
P577
2003-09-01T00:00:00Z